A Dose-Response Safety Study of ENX-102 in Patients With GAD

Key Inclusion Criteria: * Male or female, inclusive of any gender identity, aged 18 to 65 years, inclusive * Diagnosed with GAD according to the DSM-V, confirmed by MINI * Experiencing clinically significant generalized anxiety as measured by HAM-A score ≥18 and at least moderately severe core symptoms of anxious mood and tension as measured by HAM-A Items 1 and 2, respectively, with scores each ≥2 Key Exclusion Criteria: * Clinically predominant psychiatric diagnosis other than GAD per the MINI * Any past/lifetime or current diagnosis of a neurocognitive disorder or psychotic disorder, or current posttraumatic stress disorder, obsessive compulsive disorder, or bipolar disorder * Ingested prohibited medication within 5 half-lives prior to Day 1 * Current or recent moderate or severe substance use disorder as assessed by the MINI * Unwilling or unable to abstain from alcohol or other recreational psychoactive substances such as marijuana during participation in the trial * Has significant progressive disorders or unstable medical conditions * Is unable to comply with the requirements of the study or, in the opinion of the Investigator, is unsuitable for the study